Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis
Open accessAbstract
The safety, tolerance, and pharmacokinetics of amphotericin B lipid complex (ABLC) were studied in a cohort of pediatric cancer patients. Six children with hepatosplenic candidiasis (HSC) received 2.5 mg of ABLC/kg of body weight/day for 6 weeks for a total dosage of 105 mg/kg. Mean serum creatinine (0.85 +/- 0.12 mg/dl at baseline) was stable at the end of therapy at 0.85 +/- 0.18 mg/dl and at 1-month follow-up at 0.72 +/- 0.12 mg/dl. There was no increase in hepatic transaminases. Mean plasma concentrations over the dosing interval (C(ave)) and area under the curve from 0 to 24 h (AUC(0-24h)) increased between the first and seventh doses but were similar between doses 7 and 42, suggesting that steady state was achieved by day 7 of therapy. Following the final (42nd) dose of ABLC, mean AUC(0-24h) was 11.9 +/- 2.6 microg h/ml, C(ave) was 0.50 +/- 0.11 microg/ml, maximum concentration of the drug in whole blood was 1.69 +/- 0.75 microg/ml, and clearance was 3.64 +/- 0.78 ml/min/kg. Response of hepatic and splenic lesions was monitored by serial computerized tomographic and magnetic resonance imaging scans. The five evaluable patients responded to ABLC with complete or partial resolution of physical findings and of lesions of HSC. During the course of ABLC infusions and follow-up, there was no progression of HSC, breakthrough fungemia, or posttherapy recurrence. Hepatic lesions continued to resolve after the completion of administration of ABLC. Thus, ABLC administered in multiple doses to children was safe, was characterized by a steady state attainable within 1 week of therapy, and was effective in treatment of HSC.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Cites
Gibaldi, M., & Perrier, D. (1982) · CRC Press eBooks · doi:10.1201/b14095 · Cited by 4,110 · see citing works
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404 · see citing works
Self-citationHepatic Candidiasis in Cancer Patients: The Evolving Picture of the Syndrome
Thaler, M., PASTAKIA, B., SHAWKER, T. H., O’Leary, T. J., & Pizzo, P. A. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-1-88 · Cited by 394 · see citing works
Self-citationUnusual lipid structures selectively reduce the toxicity of amphotericin B.
Janoff, A. S., Boni, L. T., Popescu, M. C., Minchey, S. R., Cullis, P. R., Madden, T. D., Taraschi, T. F., Gruner, S. M., Shyamsunder, E., & Täte, M. W. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.6122 · Cited by 223 · see citing works
Anaissie, E. J., Bodey, G. P., Kantarjian, H. M., David, C. L., Barnett, K., Bow, E. J., DeFelice, R., Downs, N., File, T. M., Karam, G. A., et al. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90006-j · Cited by 217 · see citing works
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.
Lopez‐Berestein, G., Bodey, G. P., Frankel, L. S., & Mehta, K. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.2.310 · Cited by 216 · see citing works
Hepatosplenic candidiasis: Successful treatment with fluconazole
Kauffman, C. A., Bradley, S., Ross, S. C., & Weber, D. R. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90005-i · Cited by 193 · see citing works
Pharmacokinetics of Amphotericin B in Infants and Children
Starke, J. R., Mason, E. O., Kramer, W. G., & Kaplan, S. L. (1987) · The Journal of Infectious Diseases · doi:10.1093/infdis/155.4.766 · Cited by 126 · see citing works
Wiley, J. M., Smith, N., Leventhal, B. G., Graham, M. L., Strauss, L. C., Hurwitz, C. A., Modlin, J. F., Mellits, D., Baumgardner, R. A., & Corden, B. J. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.2.280 · Cited by 114 · see citing works
Focal Hepatic Candidiasis: A Distinct Clinical Variant of Candidiasis in Immunocompromised Patients
Tashjian, L. S., Abramson, J. S., & Peacock, J. E. (1984) · Clinical Infectious Diseases · doi:10.1093/clinids/6.5.689 · Cited by 98 · see citing works
Pharmacokinetics and adverse effects of amphotericin B in infants and children
Koren, G., Lau, A. S. Y., Klein, J., Golas, C. L., Bologa, M., Soldin, S. J., MacLeod, S. M., & Prober, C. G. (1988) · The Journal of Pediatrics · doi:10.1016/s0022-3476(88)80653-x · Cited by 97 · see citing works
Invasive fungal infections in children: recent advances in diagnosis and treatment.
Walsh, T. J., Gonzalez, C., Lyman, C. A., Chanock, S. J., & Pizzo, P. A. (1996) · PubMed · Cited by 93 · see citing works
Self-citationKan, V. L., Bennett, J. E., Amantea, M., Smolskis, M. C., McManus, E., Grasela, D. M., & Sherman, J. W. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/164.2.418 · Cited by 93 · see citing works
Pharmacokinetics of amphotericin B in children
Benson, J., & Nahata, M. C. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.11.1989 · Cited by 91 · see citing works
Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity
Perkins, W. R., Minchey, S. R., Boni, L. T., Swenson, C. E., Popescu, M. C., Pasternack, R. F., & Janoff, A. S. (1992) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(92)90414-h · Cited by 87 · see citing works
Cardiopulmonary Toxicity after Liposomal Amphotericin B Infusion
Levine, S. J., Walsh, T. J., Martinez, A. D., Eichacker, P. Q., Lopez‐Berestein, G., & Natanson, C. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-8-664 · Cited by 84 · see citing works
Self-citationWalsh, T. J., Garrett, K. F., Feurerstein, E., et al. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.5.1065 · Cited by 58 · see citing works
Self-citationCandidiasis of the liver and spleen in childhood.
Miller, J. H., Greenfield, L., & Wald, B. R. (1982) · Radiology · doi:10.1148/radiology.142.2.6948317 · Cited by 57 · see citing works
Manual of oncologic therapeutics
Macdonald, J. S., Haller, D. G., & Mayer, R. J. (1995) · Medical Entomology and Zoology · Cited by 46 · see citing works
Fluconazole Failure in the Treatment of Invasive Mycoses
Evans, T. G., Mayer, J., Cohen, S. P., Classen, D. A., & Carroll, K. C. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/164.6.1232 · Cited by 44 · see citing works
Candida tropicalis Infections in Children with Leukemia
Flynn, P. M., Marina, N. M., Rivera, G. K., & Hughes, W. T. (1993) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199309148562 · Cited by 36 · see citing works
Hepatosplenic candidosis ‐ a late manifestation of Candida septicemia
von Eiff, M., Fahrenkamp, A., Roos, N., Fegeler, W., & van de Loo, J. (1990) · Mycoses · doi:10.1111/myc.1990.33.6.283 · Cited by 26 · see citing works
Ringdén, O. T. H., & Tollemar, J. G. (1993) · Mycoses · doi:10.1111/j.1439-0507.1993.tb00748.x · Cited by 25 · see citing works
Walsh (1995) · doi:10.1002/1097-0142(19951201)76:11
Flagged first, then by citations
Cited by
Sorted by citations
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200 · see citing works
Self-citationPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · see citing works
Self-citationGuidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440 · see citing works
Self-citationPractice Guidelines for the Treatment of Candidiasis
Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G., Pappas, P. G., Dismukes, W. E., & Edwards, J. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313749 · Cited by 927 · see citing works
Self-citationAmphotericin B: time for a new “gold standard”
Saravolatz, L. D., Ostrosky-Zeichner, L., Marr, K. A., Rex, J. H., & Cohen, S. H. (2003) · Clinical Infectious Diseases · doi:10.1086/376634 · Cited by 406 · see citing works
Swenson, C. E., Perkins, W. R., Roberts, P., Ahmad, I., Stevens, R., Stevens, D. A., & Janoff, A. S. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.4.767 · Cited by 82 · see citing works
- Authors
- Walsh, T. J., Whitcomb, P., Piscitelli, S., Figg, W. D., Hill, S., Chanock, S. J., Jarosinski, P., Gupta, R., & Pizzo, P. A.
- Affiliations
- National Institutes of Health (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1997-09
- Volume
- 41
- Issue
- 9
- Pages
- 1944-1948
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC164041
- OpenAlex
- W1525050661
- Cited by
- 109
- References
- 24
- Citations by year
- 2025: 1 · 2024: 1 · 2022: 1 · 2021: 2 · 2020: 4 · 2019: 2 · 2018: 1 · 2017: 1 · 2016: 2 · 2015: 2 · 2014: 3 · 2013: 6 · 2012: 2
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Virginia
- Health Sciences Center, University of Oregon
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- amphotericin B lipid complex, hepatosplenic candidiasis, pediatric cancer patients, pharmacokinetics, drug safety and tolerability, antifungal therapy, drug clearance, hepatic transaminases, antifungal efficacy
- MeSH terms
- Adolescent, Amphotericin B, Antifungal Agents, Candidiasis, Child, Child, Preschool, Drug Combinations, Female, Humans, Liver Diseases, Male, Phosphatidylcholines, Phosphatidylglycerols, Splenic Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
